{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:23Z","timestamp":1786996763140,"version":"build-2736575974"},"reference-count":216,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.semarthrit.2020.09.003","type":"journal-article","created":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T10:58:32Z","timestamp":1600513112000},"page":"1226-1237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis"],"prefix":"10.1016","volume":"50","author":[{"given":"Sonsoles","family":"Piera-Velazquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Wermuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Gomez-Reino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio A.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.09.003_bib0001","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1056\/NEJMra1300575","article-title":"Fibrosis\u2013a common pathway to organ injury and failure","volume":"372","author":"Rockey","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7113-8_1","article-title":"Human fibrotic diseases: current challenges in fibrosis research","volume":"1627","author":"Rosenbloom","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0003","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm0511-552","article-title":"Scraping fibrosis: Expressway to the core of fibrosis","volume":"17","author":"Mehal","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0004","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mam.2018.06.003","article-title":"Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications","volume":"65","author":"Weiskirchen","year":"2019","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0006","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.7326\/0003-4819-152-3-201002020-00007","article-title":"Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies","volume":"152","author":"Rosenbloom","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0008","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0009","first-page":"697","article-title":"Toxic epidemic syndrome, Spain, 1981","volume":"2","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0010","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/00002281-199411000-00016","article-title":"Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia","volume":"6","author":"Bolster","year":"1994","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0011","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00000372-200110000-00001","article-title":"Nephrogenic fibrosing dermopathy","volume":"23","author":"Cowper","year":"2001","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0012","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/01.bor.0000245725.94887.8d","article-title":"Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)","volume":"18","author":"Galan","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0013","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-med-063014-124936","article-title":"Gadolinium-induced fibrosis","volume":"67","author":"Todd","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0014","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ncprheum0115","article-title":"Mechanisms and consequences of fibrosis in Systemic Sclerosis","volume":"2","author":"Denton","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0015","doi-asserted-by":"crossref","unstructured":"TrojanowskaM, VargaJ.Molecular pathways as novel therapeutic targets in Systemic Sclerosis. 2007; 19:568-73.","DOI":"10.1097\/BOR.0b013e3282e6f495"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0016","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/BOR.0b013e3282f00375","article-title":"Understanding systemic sclerosis through gene expression profiling","volume":"19","author":"Pendergrass","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0017","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrrheum.2014.128","article-title":"The role of genetics and epigenetics in the pathogenesis of Systemic Sclerosis","volume":"10","author":"Broen","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0018","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrrheum.2014.53","article-title":"Fibrosis\u2014a lethal component of systemic sclerosis","volume":"10","author":"Ho","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0019","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/gene.2014.44","article-title":"Emerging role of epigenetics in Systemic Sclerosis pathogenesis","volume":"15","author":"Ciechomska","year":"2014","journal-title":"Genes Immun"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00109-014-1190-x","article-title":"Molecular and cellular basis of Scleroderma","volume":"92","author":"Eckes","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0021","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/1346-8138.14153","article-title":"Systemic Sclerosis","volume":"45","author":"Asano","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0022","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0140-6736(81)90949-1","article-title":"Toxic-allergic syndrome caused by ingestion of rapeseed oil denaturated with aniline","volume":"2","author":"Tabuenca","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0023","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00496569","article-title":"Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain","volume":"397","author":"Martinez-Tello","year":"1982","journal-title":"Virchows Arch Path Anat"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0024","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJM198312083092302","article-title":"Clinical epidemiology of the toxic oil syndrome. Manifestations of a new illness","volume":"309","author":"Kilbourne","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0049-0172(05)80017-4","article-title":"Toxic oil syndrome and eosinophilia-myalgia syndrome: May 8-10, 1991, World Health Organization meeting report","volume":"23","author":"Philen","year":"1993","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0026","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0049-0172(86)90017-X","article-title":"Toxic oil syndrome: a syndrome with features overlapping those of various forms of scleroderma","volume":"15","author":"Alonso-Ruiz","year":"1986","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0027","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00005792-199309000-00001","article-title":"Toxic oil syndrome. A long-term follow-up of a cohort of 332 patients","volume":"72","author":"Alonso-Ruiz","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0028","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ije\/27.6.1057","article-title":"Toxic oil syndrome mortality: The first 13 years","volume":"27","author":"Abaitua Borda","year":"1998","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0029","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/oxfordjournals.epirev.a000804","article-title":"Toxic oil syndrome: the perspective after 20 years","volume":"23","author":"Posada de la Paz","year":"2001","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0030","first-page":"457","article-title":"The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge","volume":"110","author":"Gelp\u00ed","year":"2002","journal-title":"Environ Health Perspect"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0031","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0895-4356(03)00119-7","article-title":"Toxic oil syndrome: survival in the whole cohort between 1981 and 1995","volume":"56","author":"S\u00e1nchez-Porro Valad\u00e9s","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0032","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/oxfordjournals.aje.a114914","article-title":"Chemical correlates of pathogenicity of oils related to the toxic oil syndrome in Spain","volume":"127","author":"Kilbourne","year":"1988","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0033","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00001648-199903000-00008","article-title":"Epidemiologic evidence for a new class of compounds associated with toxic oil syndrome","volume":"10","author":"Posada de la Paz","year":"1999","journal-title":"Epidemiology"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0034","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cbi.2011.01.004","article-title":"Contribution of denaturing and deodorization processes of oils to toxic oil syndrome","volume":"192","author":"Ruiz-M\u00e9ndez","year":"2011","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0035","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cbi.2010.10.006","article-title":"Potential implication of aniline derivatives in the Toxic Oil Syndrome (TOS)","volume":"192","author":"Messeguer","year":"2011","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0036","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1378\/chest.95.2.325","article-title":"Pulmonary hypertension due to toxic oil syndrome: a clinicopathologic study. A study of seven deaths due to late, severe pulmonary hypertension","volume":"95","author":"Gomez-Sanchez","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0037","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/0002-8703(91)90192-K","article-title":"Histological abnormalities of large and small coronary arteries, neural structures and the conduction system of the heart found in postmortem studies of individuals dying from the toxic oil syndrome","volume":"121","author":"James","year":"1991","journal-title":"Am Heart J"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0038","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0735-1097(91)90764-Z","article-title":"Extracardiac vascular and neural lesions in the toxic oil syndrome","volume":"18","author":"Martinez-Tello","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0039","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/0735-1097(91)90688-6","article-title":"Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome","volume":"18","author":"Gomez-Sanchez","year":"1991","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0040","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/clc.4960170902","article-title":"The toxic oil syndrome","volume":"17","author":"James","year":"1994","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0041","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1136\/thx.38.10.724","article-title":"Pulmonary vascular lesions in the toxic oil syndrome in Spain","volume":"38","author":"Fern\u00e1ndez-Segoviano","year":"1983","journal-title":"Thorax"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0042","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2249.1993.tb06504.x","article-title":"Expression of types I, III and IV collagen genes in fibrotic skin and nerve lesions of Toxic Oil Syndrome patients","volume":"93","author":"Gomez-Reino","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0043","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/15476910590960143","article-title":"Review article toxic oil syndrome: review of immune aspects of the disease","volume":"2","author":"Patterson","year":"2005","journal-title":"J Immunotoxicol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0044","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0300-483X(94)90085-X","article-title":"Immunological basis of Toxic Oil Syndrome (TOS)","volume":"93","author":"Gallardo","year":"1994","journal-title":"Toxicology"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/978-3-642-60682-3_6","article-title":"Immunological aspects of the toxic oil syndrome","volume":"19","author":"Lahoz","year":"1997","journal-title":"Arch Toxicol Suppl"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0046","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1006\/rtph.1994.1006","article-title":"The toxic oil syndrome: a perspective on immunotoxicological mechanisms","volume":"19","author":"Yoshida","year":"1994","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0047","first-page":"69","article-title":"Antiphospholipid antibodies in patients with Eosinophilia Myalgia and Toxic Oil Syndrome","volume":"24","author":"Carreira","year":"1997","journal-title":"J Rheumatol"},{"issue":"8423","key":"10.1016\/j.semarthrit.2020.09.003_bib0048","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(85)91045-1","article-title":"Collagen antibodies in toxic oil disease","volume":"1","author":"Pereira","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0049","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/jaut.1995.0022","article-title":"Autoantibodies to cryptic epitopes of c-reactive protein and other acute phase proteins in the Toxic Oil Syndrome","volume":"8","author":"Bell","year":"1995","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2249.1990.tb05445.x","article-title":"Participation of eosinophils in the toxic oil syndrome","volume":"82","author":"Ten","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0051","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archderm.1994.01690010045005","article-title":"Fibrogenic growth factors in the Eosinophilia-Myalgia Syndrome and the Toxic Oil Syndrome","volume":"130","author":"Kaufman","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0052","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.toxlet.2005.09.027","article-title":"Genetic approaches in the understanding of Toxic Oil Syndrome","volume":"161","author":"Cardaba","year":"2006","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0053","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.toxlet.2005.05.009","article-title":"Toxic oil syndrome: Genetic restriction and immunomodulatory effects due to adulterated oils in a model of HLA transgenic mice","volume":"159","author":"Gallardo","year":"2005","journal-title":"Toxic Lett"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0054","first-page":"765","article-title":"Eosinophilia-myalgia syndrome\u2014New Mexico","volume":"38","year":"1989","journal-title":"MMWR"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0055","first-page":"587","article-title":"Update: eosinophilia-myalgia syndrome associated with the ingestion of L-tryptophan\u2014United States, through August 24, 1990","volume":"39","year":"1990","journal-title":"MMWR"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0056","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1056\/NEJM199003293221301","article-title":"Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan","volume":"322","author":"Hertzman","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0057","first-page":"867","article-title":"The eosinophilia-myalgia syndrome: the Los Alamos Conference","volume":"18","author":"Hertzman","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0058","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1056\/NEJM199003293221302","article-title":"Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan","volume":"322","author":"Silver","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0059","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7326\/0003-4819-113-2-124","article-title":"The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion","volume":"113","author":"Martin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0060","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1001\/jama.1990.03440110068030","article-title":"Tryptophan-associated eosinophilic connective-tissue disease. A new clinical entity?","volume":"263","author":"Clauw","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0061","first-page":"1534","article-title":"Eosinophilia-myalgia syndrome associated with L-tryptophan use","volume":"17","author":"Glickstein","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0062","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/archinte.1990.00390210132029","article-title":"Eosinophilia-myalgia syndrome associated with L-tryptophan ingestion","volume":"150","author":"Strongwater","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0063","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0049-0172(90)90069-R","article-title":"Clinical spectrum of the systemic manifestations of the eosinophilia-myalgia syndrome","volume":"19","author":"Varga","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0064","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00005792-199007000-00001","article-title":"L-Tryptophan associated eosinophilic perimyositis, neuritis, and fasciitis. A clinicopathologic and laboratory study of 25 patients","volume":"69","author":"Kaufman","year":"1990","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0065","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ana.410280409","article-title":"Peripheral neuropathy associated with the eosinophilia-myalgia syndrome","volume":"28","author":"Heiman-Patterson","year":"1990","journal-title":"Ann Neurol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0066","first-page":"1544","article-title":"Microangiopathy in the eosinophilia-myalgia syndrome","volume":"17","author":"Smith","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0067","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-0381-7_55","article-title":"Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome","volume":"398","author":"Smith","year":"1996","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0068","doi-asserted-by":"crossref","first-page":"102","DOI":"10.7326\/0003-4819-115-2-102","article-title":"Postmortem studies of the heart in three fatal cases of the eosinophilia-myalgia syndrome","volume":"115","author":"James","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0069","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0025-6196(12)61043-X","article-title":"Restrictive cardiomyopathy associated with the eosinophilia-myalgia syndrome","volume":"69","author":"Berger","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0070","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1378\/chest.97.5.1032","article-title":"Pulmonary disease associated with L-tryptophan-induced eosinophilic myalgia syndrome. Clinical and pathologic features","volume":"97","author":"Tazeelar","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0071","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/BF02242958","article-title":"Eosinophilic hepatitis: a new feature of the clinical spectrum of the eosinophilia-myalgia syndrome","volume":"13","author":"Martinez-Osuna","year":"1994","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0072","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0046-8177(92)90091-G","article-title":"Pathologic manifestations of the eosinophilia myalgia syndrome: analysis of 11 cases","volume":"23","author":"Lin","year":"1992","journal-title":"Hum Pathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0073","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00005072-199101000-00004","article-title":"The neuromuscular pathology of the eosinophilia-myalgia syndrome","volume":"50","author":"Seidman","year":"1991","journal-title":"J Neuropath Exp Neurol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0074","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0046-8177(91)90054-S","article-title":"Neuromuscular manifestations of L-tryptophan-associated eosinophilia-myalgia syndrome: a histomorphologic analysis of 14 patients","volume":"22","author":"Verity","year":"1991","journal-title":"Hum Pathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0075","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jama.1990.03450020065028","article-title":"Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer","volume":"264","author":"Slutsker","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0076","first-page":"81","article-title":"Tryptophan produced by Showa Denko and epidemic Eosinophilia-Myalgia Syndrome","volume":"46","author":"Kilbourne","year":"1996","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0077","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199008093230601","article-title":"An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use","volume":"323","author":"Belongia","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0078","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1126\/science.2270484","article-title":"Characterization of \"peak E\": a novel amino acid associated with the eosinophilia-myalgia syndrome","volume":"250","author":"Mayeno","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0079","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF00230724","article-title":"Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome","volume":"25","author":"Hill","year":"1993","journal-title":"Arch Environ Contam Toxicol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-4274(97)00048-9","article-title":"On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome","volume":"92","author":"Williamson","year":"1997","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0081","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0378-4274(98)00223-9","article-title":"On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome","volume":"99","author":"Williamson","year":"1998","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0082","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.toxlet.2017.10.012","article-title":"Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome","volume":"282","author":"Klarskov","year":"2018","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0083","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.toxlet.2018.05.027","article-title":"Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome","volume":"294","author":"Klarskov","year":"2018","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0084","doi-asserted-by":"crossref","first-page":"140","DOI":"10.7326\/0003-4819-116-2-140","article-title":"The cause and pathogenesis of the eosinophilia\u2010myalgia syndrome","volume":"116","author":"Varga","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0085","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1038\/jid.1993.31","article-title":"L-tryptophan and the eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis","volume":"100","author":"Varga","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0086","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/978-1-4613-0381-7_50","article-title":"Pathogenesis of L-tryptophan eosinophilia myalgia syndrome","volume":"398","author":"Sternberg","year":"1996","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0087","first-page":"26","article-title":"Pathophysiology of the eosinophilia-myalgia syndrome","volume":"46","author":"Silver","year":"1996","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0088","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0140-6736(91)91717-9","article-title":"Clinical follow-up and immunogenetic studies of 32 patients with the eosinophilia-myalgia syndrome","volume":"337","author":"Kaufman","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0089","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.24460","article-title":"Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms","volume":"61","author":"Okada","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0090","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ana.410290512","article-title":"Eosinophilia myalgia syndrome: I. Immunocytochemical evidence for a T-cell-mediated immune effector response","volume":"29","author":"Emslie-Smith","year":"1991","journal-title":"Ann Neurol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0091","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/0003-4819-112-5-344","article-title":"Development of diffuse fasciitis with eosinophilia during L-tryptophan treatment: demonstration of elevated type I collagen gene expression in affected tissues","volume":"112","author":"Varga","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0092","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1002\/art.30514","article-title":"Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan","volume":"63","author":"Allen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0093","first-page":"1307","article-title":"The eosinophil as a cellular source of transforming growth factor alpha in healing cutaneous wounds","volume":"138","author":"Todd","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0094","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/1523-1747.ep12514683","article-title":"Elevated expression of the genes for transforming growth factor-\u03b21 and type VI collagen in diffuse fasciitis associated with the eosinophilia-myalgia syndrome","volume":"96","author":"Peltonen","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0095","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","article-title":"Scleromyxoedema-like cutaneous diseases in renal-dialysis patients","volume":"356","author":"Cowper","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0096","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1067\/mjd.2003.78","article-title":"Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease","volume":"48","author":"Mackay-Wiggan","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0097","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0002-9343(03)00085-8","article-title":"Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure","volume":"114","author":"Swartz","year":"2003","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0098","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1067\/mjd.2003.77","article-title":"Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases","volume":"48","author":"Streams","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0099","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1046\/j.1525-139X.2003.16053.x","article-title":"Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease","volume":"16","author":"Perazella","year":"2003","journal-title":"Semin Dial"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.139.7.903","article-title":"Nephrogenic fibrosing dermopathy with systemic involvement","volume":"139","author":"Ting","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0101","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/art.20362","article-title":"Dialysis-associated systemic fibrosis (Nephrogenic Fibrosing Dermopathy)","volume":"50","author":"Jimenez","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0102","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/mus.20153","article-title":"Involvement of skeletal muscle in dialysis-associated fibrosis (Nephrogenic Fibrosing Dermopathy)","volume":"30","author":"Levine","year":"2004","journal-title":"Muscle & Nerve"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0103","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2005.08.002","article-title":"Description of twelve cases of nephrogenic fibrosing dermopathy and review of the literature","volume":"35","author":"Mendoza","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0104","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00428-006-0246-x","article-title":"Nephrogenic fibrosing dermopathy with involvement of the dura mater","volume":"449","author":"Saenz","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0105","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5858\/2006-130-209-MIINFD","article-title":"Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature","volume":"130","author":"Gibson","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0106","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/00002281-200311000-00017","article-title":"Nephrogenic fibrosing dermopathy: the first 6 years","volume":"15","author":"Cowper","year":"2003","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0107","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1540-9740.2007.05829.x","article-title":"Nephrogenic systemic fibrosis\/nephrogenic fibrosing dermopathy: clinical aspects","volume":"6","author":"Piera-Vel\u00e1zquez","year":"2007","journal-title":"Skinmed"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0108","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.5858\/133.12.1943","article-title":"Nephrogenic systemic fibrosis: a pathologic study of autopsy cases","volume":"133","author":"Koreishi","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0109","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1148\/radiol.2431062144","article-title":"Nephrogenic systemic fibrosis: risk factors and incidence estimation","volume":"243","author":"Sadowski","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0110","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1148\/radiol.2019182916","article-title":"A systematic review of 639 patients with biopsy-confirmed nephrogenic systemic fibrosis","volume":"292","author":"Attari","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0111","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ndt\/gfk062","article-title":"Gadolinium \u2013 a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?","volume":"21","author":"Grobner","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0112","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1681\/ASN.2006060601","article-title":"Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging","volume":"17","author":"Marckmann","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0113","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1259\/bjr\/17111243","article-title":"Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?","volume":"80","author":"Morcos","year":"2007","journal-title":"Br J Radiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0114","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1148\/radiol.2451070353","article-title":"Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort","volume":"245","author":"Collidge","year":"2007","journal-title":"Radiology"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ejrad.2008.02.011","article-title":"Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting","volume":"66","author":"Broome","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0116","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/RLI.0b013e31815a3407","article-title":"High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent","volume":"43","author":"Rydahl","year":"2008","journal-title":"Invest Radiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0117","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1148\/radiol.2483071863","article-title":"Incidence of nephrogenic systemic fibrosis at two large medical centers","volume":"248","author":"Prince","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0118","unstructured":"U.S. Food and Drug Administration. Public health advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMark, Magnevist, ProHance, and MultiHance. June 8, 2006. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/PublicHealthAdvisories\/ucm053112.htm."},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0119","unstructured":"U.S. Food and Drug Administration. Information for healthcare professionals. Gadolinium-based contrast agents for magnetic resonance imaging marketed as Magnevist, MultiHance, Omniscan, OptiMark, ProHance). May 23, 2007. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm142905.htm."},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0120","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm223966.htm."},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0121","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaad.2006.10.047","article-title":"Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis","volume":"56","author":"High","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0122","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/jmicro\/dfm020","article-title":"Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin","volume":"56","author":"Thakral","year":"2007","journal-title":"J Electron Microsc"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0123","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cmmi.146","article-title":"Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications","volume":"2","author":"Thakral","year":"2007","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0124","first-page":"272","article-title":"Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis","volume":"158","author":"Abraham","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0125","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1600-0560.2009.01283.x","article-title":"Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis","volume":"36","author":"Thakral","year":"2009","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0126","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.04.010","article-title":"Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with an analysis of clinical factors","volume":"59","author":"Khurana","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0127","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2214\/AJR.07.2822","article-title":"Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue","volume":"190","author":"Wiginton","year":"2008","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0128","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2133.2010.09918.x","article-title":"Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in nephrogenic systemic fibrosis","author":"George","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2009.12.044","article-title":"Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis","volume":"64","author":"Christensen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaad.2009.07.018","article-title":"Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy","volume":"62","author":"High","year":"2010","journal-title":"J. Am Acad Dermatol."},{"issue":"6","key":"10.1016\/j.semarthrit.2020.09.003_bib0131","article-title":"An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0132","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2230.2011.04136.x","article-title":"Pathomechanisms of Nephrogenic Systemic Fibrosis: New insights","volume":"36","author":"Gupta","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0133","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/912189","article-title":"Understanding nephrogenic systemic fibrosis","volume":"2012","author":"Chopra","year":"2012","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0134","doi-asserted-by":"crossref","first-page":"427","DOI":"10.4329\/wjr.v2.i11.427","article-title":"Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data","volume":"2","author":"Morcos","year":"2010","journal-title":"World J Radiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0135","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jmri.21980","article-title":"Mechanism of NSF: New evidence challenging the prevailing theory","volume":"30","author":"Newton","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0136","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00467-013-2636-z","article-title":"Gadolinium and nephrogenic systemic fibrosis: an update","volume":"29","author":"Weller","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0137","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.00166.2016","article-title":"Pathophysiology of gadolinium-associated systemic fibrosis","volume":"311","author":"Wagner","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0138","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.24471","article-title":"Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents","volume":"60","author":"Wermuth","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0139","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1136\/ard.2010.134858","article-title":"NF\u03baB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis","volume":"69","author":"Del Galdo","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.etp.2008.11.004","article-title":"The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis \u2013 a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide","volume":"61","author":"Steger-Hartmann","year":"2009","journal-title":"Exp Toxicol Pathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0141","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1053\/j.ajkd.2010.01.021","article-title":"Balance of profibrotic and antifibrotic signaling in nephrogenic systemic fibrosis skin lesions","volume":"55","author":"Schieren","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0142","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1136\/ard.2009.127761","article-title":"Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis","volume":"69","author":"Piera-Velazquez","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0143","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2353\/ajpath.2010.091095","article-title":"Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis","volume":"177","author":"Del Galdo","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0144","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03403533","article-title":"Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair","volume":"1","author":"Bucala","year":"1994","journal-title":"Mol Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.4049\/jimmunol.160.1.419","article-title":"Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes","volume":"160","author":"Chesney","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0146","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00401-018-1857-4","article-title":"Gadolinium-based contrast agents induce gadolinium deposits in cerebral vessel walls, while the neuropil is not affected: an autopsy study","volume":"136","author":"Fingerhut","year":"2018","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.003_bib0147","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2007.12.004","article-title":"Scleroderma-like disorders","volume":"7","author":"Foti","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0148","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.rdc.2007.11.001","article-title":"Scleroderma-like fibrosing disorders","volume":"34","author":"Boin","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0149","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11926-011-0220-8","article-title":"Scleroderma mimics","volume":"14","author":"Nashel","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.09.003_bib0150","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/01.bor.0000434599.51526.47","article-title":"The differential diagnosis of systemic sclerosis","volume":"25","author":"Tyndall","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.003_bib0151","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12016-017-8625-4","article-title":"Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review","volume":"53","author":"Ferreli","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0152","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"8325","key":"10.1016\/j.semarthrit.2020.09.003_bib0153","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0140-6736(83)91812-3","article-title":"Autoimmunnity in patients with Spanish toxic oil syndrome","volume":"1","author":"Gutierrez","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0154","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/clin.1995.1104","article-title":"Autoantibodies in sera from patients with L-tryptophan-associated eosinophilia-myalgia syndrome. Demonstration of unique antigen-antibody specificities","volume":"76","author":"Kaufman","year":"1995","journal-title":"Clin Immunol Immunopathol"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.09.003_bib0155","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/mus.880160910","article-title":"Chronic immune activation in the eosinophilia-myalgia syndrome","volume":"16","author":"McKinley","year":"1993","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0156","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/art.1780350116","article-title":"Autoantibodies to nuclear lamin C in the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion","volume":"35","author":"Varga","year":"1992","journal-title":"Arthritis and Rheumatism"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0157","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature06881","article-title":"The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins","volume":"453","author":"Veldhoen","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0158","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature06880","article-title":"Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor","volume":"453","author":"Quintana","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0159","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.imlet.2009.11.008","article-title":"AHR activation by tryptophan\u2013pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome?","volume":"128","author":"Rieber","year":"2010","journal-title":"Immunol Lett"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.09.003_bib0160","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/archderm.1955.03730360041004","article-title":"Progressive systemic sclerosis; visceral manifestations in generalized scleroderma","volume":"72","author":"Piper","year":"1955","journal-title":"AMA Arch Derm"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.003_bib0161","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0002-9343(69)90044-8","article-title":"Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls","volume":"46","author":"D\u2019Angelo","year":"1969","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.003_bib0162","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0002-9343(57)90324-8","article-title":"Renal involvement in progressive systemic sclerosis (generalized scleroderma)","volume":"23","author":"Rodnan","year":"1957","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0163","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1378\/chest.44.4.374","article-title":"Pulmonary Vascular Lesions in Systemic Scleroderma","volume":"44","author":"Naeye","year":"1963","journal-title":"Dis Chest"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.003_bib0164","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-73-2-317","article-title":"Vascular disease in progressive systemic sclerosis (scleroderma)","volume":"73","author":"Norton","year":"1970","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.09.003_bib0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0049-0172(75)90017-7","article-title":"Pathogenesis of systemic sclerosis: a vascular hypothesis","volume":"4","author":"Campbell","year":"1975","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0166","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.rdc.2007.12.004","article-title":"Vascular disease in scleroderma: mechanisms of vascular injury","volume":"34","author":"Kahaleh","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.09.003_bib0167","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11926-009-0015-3","article-title":"Is scleroderma a vasculopathy?","volume":"11","author":"Fleming","year":"2009","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0168","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.rdc.2008.01.001","article-title":"The pathology of scleroderma vascular disease","volume":"34","author":"Fleming","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"2-3","key":"10.1016\/j.semarthrit.2020.09.003_bib0169","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s12016-008-8106-x","article-title":"Vascular disease in scleroderma","volume":"36","author":"Wigley","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0170","article-title":"Vascular disease in systemic sclerosis","volume":"2010","author":"Chung","year":"2010","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0171","article-title":"The vascular microenvironment and systemic sclerosis","volume":"2010","author":"Frech","year":"2010","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0172","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","article-title":"Review: evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.09.003_bib0173","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1084\/jem.149.6.1326","article-title":"Endothelial injury in scleroderma","volume":"149","author":"Kahaleh","year":"1979","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0174","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1006\/clin.1996.4322","article-title":"Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera","volume":"83","author":"Kahaleh","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/BOR.0000000000000112","article-title":"Endothelial dysfunction in systemic sclerosis","volume":"26","author":"Altorok","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0176","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of EC in the vasculopathy of systemic sclerosis: A systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0177","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.semcdb.2019.10.015","article-title":"Endothelium-mediated contributions to fibrosis","volume":"101","author":"Sun","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0178","article-title":"Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis","author":"Ota","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0179","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-319-57613-8_4","article-title":"Endothelial Cells","volume":"1003","author":"Sturtzel","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0180","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.autrev.2017.07.008","article-title":"Endothelial Cells: From innocent bystanders to active participants in immune responses","volume":"16","author":"Al-Soudi","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0181","first-page":"4","article-title":"The endothelium: Global Integrator of Vascular-Immune Interactions","volume":"1","author":"Bergey","year":"2019","journal-title":"J Cell Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0182","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1073\/pnas.0809403105","article-title":"Immunostimulatory activity of haptenated proteins","volume":"106","author":"Palm","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.09.003_bib0183","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214202","article-title":"Autoantibodies are present before the clinical diagnosis of systemic sclerosis","volume":"14","author":"Burbelo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0184","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nm1613","article-title":"Endothelial-to-mesenchymal transition contributes to cardiac fibrosis","volume":"13","author":"Zeisberg","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0185","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ajpath.2011.06.001","article-title":"Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders","volume":"179","author":"Piera-Velazquez","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0186","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/iub.1059","article-title":"The role of endothelial-mesenchymal transition in development and pathological process","volume":"64","author":"Lin","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0187","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1161\/CIRCULATIONAHA.116.022479","article-title":"Endothelial-to-mesenchymal transition","volume":"133","author":"Stenmark","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0188","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1152\/physrev.00021.2018","article-title":"Endothelial to mesenchymal transition: role in physiology and in the pathogenesis of human diseases","volume":"99","author":"Piera-Velazquez","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0189","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tcm.2009.01.001","article-title":"Transforming growth factor beta-induced endothelial-to-mesenchymal transition: a switch to cardiac fibrosis?","volume":"18","author":"Goumans","year":"2008","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1042\/BJ20101500","article-title":"Transforming growth factor-\u03b22 promotes Snail-mediated endothelial-mesenchymal transition through convergence of Smad-dependent and Smad-independent signalling","volume":"437","author":"Medici","year":"2011","journal-title":"Biochem J"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.09.003_bib0191","doi-asserted-by":"crossref","first-page":"E2157","DOI":"10.3390\/ijms18102157","article-title":"TGF-\u03b2-induced endothelial-mesenchymal transition in fibrotic diseases","volume":"18","author":"Pardali","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0192","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00441-011-1222-6","article-title":"Regulation of endothelial cell plasticity by TGF-\u03b2","volume":"347","author":"van Meeteren","year":"2012","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0193","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cytogfr.2016.09.002","article-title":"Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions","volume":"33","author":"P\u00e9rez","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0194","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/art.30317","article-title":"Protein kinase C\u03b4 and c-Abl kinase are required for transforming growth factor \u03b2 induction of endothelial-mesenchymal transition in vitro","volume":"63","author":"Li","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2020.09.003_bib0195","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1755-1536-5-S1-S7","article-title":"Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases","volume":"5","author":"Piera-Velazquez","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0196","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00002281-200011000-00008","article-title":"Systemic sclerosis: environmental and occupational risk factors","volume":"12","author":"Nietert","year":"2000","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0197","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/BOR.0b013e32835cfc2d","article-title":"Environmental risk factors in systemic sclerosis","volume":"25","author":"Dospinescu","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0198","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00281-015-0507-3","article-title":"Environmental risk factors of systemic sclerosis","volume":"37","author":"Marie","year":"2015","journal-title":"Semin Immunopathol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.09.003_bib0199","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3899\/jrheum.090207","article-title":"Systemic sclerosis: environmental factors","volume":"36","author":"Mora","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0200","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.autrev.2018.11.001","article-title":"Systemic sclerosis and exposure to heavy metals","volume":"18","author":"Marie","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0201","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10067-016-3533-1","article-title":"Occupational and environmental scleroderma. Systemic review and meta-analysis","volume":"36","author":"Rubio-Rivas","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0202","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/0961203311430703","article-title":"Silicone and scleroderma revisited","volume":"21","author":"Lidar","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0203","article-title":"A follow-up study of occupational styrene exposure and risk of autoimmune rheumatic diseases","author":"Hjuler Boudigaard","year":"2019","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0204","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.autrev.2008.07.022","article-title":"Systemic sclerosis and infections","volume":"8","author":"Randone","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0205","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/867389","article-title":"Possible role of human herpesvirus 6 as a trigger of autoimmune disease","volume":"2013","author":"Broccolo","year":"2013","journal-title":"Sci World J"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-015-0552-x","article-title":"Fresh insights into disease etiology and the role of microbial pathogens","volume":"18","author":"Farina","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.09.003_bib0207","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms8010039","article-title":"HHV-6A infection and systemic sclerosis: clues of a possible association","volume":"8","author":"Caselli","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0208","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00281-015-0505-5","article-title":"Vasculopathy in scleroderma","volume":"37","author":"Asano","year":"2015","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0209","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3389\/fimmu.2018.02045","article-title":"Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed?","volume":"9","author":"Bruni","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0210","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3389\/fimmu.2018.02191","article-title":"Single cell RNA sequencing identifies HSPG2 and APLNR as markers of endothelial cell injury in systemic sclerosis skin","volume":"9","author":"Apostolidis","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0211","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.trsl.2019.02.010","article-title":"Evolving insights into the cellular and molecular pathogenesis of fibrosis in systemic sclerosis","volume":"209","author":"Korman","year":"2019","journal-title":"Transl Res"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0212","first-page":"471","article-title":"The vessels contribute to fibrosis in systemic sclerosis","volume":"21","author":"Di Benedetto","year":"2019","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0213","article-title":"Role of endothelial to mesenchymal transition in the pathogenesis of the vascular alterations in systemic sclerosis","volume":"2013","author":"Jimenez","year":"2013","journal-title":"ISRN Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0214","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0215","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.150088","article-title":"The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-\u03b2 and may be blocked by macitentan, a dual endothelin-1 receptor antagonist","volume":"42","author":"Cipriani","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.09.003_bib0216","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1152\/physrev.00021.2018","article-title":"Endothelial to mesenchymal transition: role in physiology and in the pathogenesis of human diseases","volume":"99","author":"Piera-Velazquez","year":"2019","journal-title":"Physiol Rev"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:03:16Z","timestamp":1758733396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":216,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0049017220302493"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}